



Cover image: Knee joint of arthritic mouse (B). Knee joint of a mouse treated with CO-releasing molecule (CORM)-3. (See p1211)

Editor

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
Dimitrios Boumpas
Gerd Burmester
Mary Crow

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com

ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Impact Factor: 6.411

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2008 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission. ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK.

Annals of the Rheumatic Diseases (USPS No: 002-152) is published monthly by BMJ Publishing Group and distributed in the USA by SPP, 75 Aberdeen Road, Emigsville, PA 17318, USA. Periodicals postage paid at Emigsville, PA, USA. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, PO Box 437, Emigsville, PA 17318-0437, USA.

Editorial

- 1201** Arthritis and endogenous glucocorticoids: the emerging role of the 11 β -HSD enzymes
F Buttgeriet, H Zhou, M J Seibel

Extended reports

- 1204** Local and systemic glucocorticoid metabolism in inflammatory arthritis
R Hardy, E H Rabbitt, A Filer, P Emery, M Hewison, P M Stewart, N J Gittos, C D Buckley, K Raza, M S Cooper
- 1211** Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis
M L Ferrándiz, N Maicas, I Garcia-Arnanadis, M C Terencio, R Motterlini, I Devesa, L A B Joosten, W B van den Berg, M J Alcaraz
- 1218** Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
D van der Heijde, A L Pangan, M H Schiff, J Braun, M Borofsky, J Torre, J C Davis Jr, R L Wong, H Kupper, E Collantes, for the ATLAS Study Group
- 1222** Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases
C P Denton, J E Pope, H-H Peter, A Gabrielli, A Boonstra, F H J van den Hoogen, G Riemekasten, S De Vita, A Morganti, M Dölberg, O Berkani, L Guillevin, (on behalf of the TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators)
- 1229** The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data
W Kievit, E M Adang, J Fransen, H H Kuper, M A F J van de Laar, T L Jansen, C M A De Gendt, D-J R A M De Rooij, H L M Brus, P C M Van Oijen, P C L M Van Riel
- 1235** Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells
L Salazar, O Aravena, P Abello, A Escobar, J Contreras-Levicoy, N Rojas-Colonelli, D Catalán, A Aguirre, R Zúñiga, B Pesce, C González, R Cepeda, M Cuchacovich, M C Molina, F Salazar-Onfray, M Delgado, R E Toes, J C Aguillón
- 1242** COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker
R Hesselstrand, A Kassner, D Heinegård, T Saxne
- 1249** High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study
P Szulc, A Montella, P D Delmas

- 1256** Association between leptin, body composition, sex and knee cartilage morphology in older adults: the Tasmanian older adult cohort (TASOAC) study
C Ding, V Parameswaran, F Cicuttini, J Burgess, G Zhai, S Quinn, G Jones
- 1262** Corticosteroid injections effective for trigger finger in adults in general practice: a double-blinded randomised placebo controlled trial
C Peters-Veluthamaningal, J C Winters, K H Groenier, B Meyboom-de Jong
- 1267** Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial
D van der Heijde, R Landewé, R van Vollenhoven, S Fatenejad, L Klareskog
- 1271** Clinical features and risk factors of postsurgical gout
E H Kang, E Y Lee, Y J Lee, Y W Song, E B Lee
- 1276** MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis
M Rudwaleit, S Schwarzlose, E S Hilgert, J Listing, J Braun, J Sieper
- 1282** Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study
B Rozman, S Čučnik, S Sodin-Semrl, L Czirájk, C Varjú, O Distler, D Huscher, M Aringer, G Steiner, M Matucci-Cerini, S Guiducci, B Stamenković, A Stanković, T Kveder
- 1287** The *FCRL3* –169T>C polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a Scandinavian panel of autoimmune diseases
M C Eike, G B N Nordang, T H Karlsen, K M Boberg, M H Vatn on behalf of the IBSEN study group, K Dahl-Jørgensen, K S Rønningen, G Joner, B Flato, A Bergquist, E Thorsby, Ø Førre, T K Kvien, D E Undlien, B A Lie

MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk



- 1292** Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment
S Stojanov, C DeJaco, P Lohse, K Huss, C Duftner, B H Belohradsky, M Herold, M Schirmer
- 1299** Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis
H Yamada, Y Nakashima, K Okazaki, T Mawatari, J-I Fukushi, N Kaibara, A Hori, Y Iwamoto, Y Yoshikai
- 1305** Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis
A-M Sims, A E Timms, J Bruges-Armas, R Burgos-Vargas, C-T Chou, T Doan, A Dowling, R N Fialho, P Gergely, D D Gladman, R Inman, M Kauppi, K Kaarela, K Laiho, W Maksymowycz, J J Pointon, P Rahman, J D Reveille, R Sorrentino, J Tuomilehto, G Vargas-Alarcon, B P Wordsworth, H Xu, M A Brown, on behalf of the International Genetics of Ankylosing Spondylitis
- 1310** Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans
J A Singh, V Strand
- 1317** Oesophageal dilatation on high-resolution computed tomography scan of the lungs as a sign of scleroderma
M C Vonk, C E van Die, M M Snoeren, K J Bhansing, P L C M van Riel, J Fransen, F H J van den Hoogen
- 1322** Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)
M Walsh, A Chaudhry, D Jayne
- 1328** The Mal/TIRAP S180L and TLR4 G299D polymorphisms are not associated with susceptibility to, or severity of, rheumatoid arthritis
F J Sheedy, I Marinou, L A J O'Neill, A G Wilson
- 1332** Early and long-lasting protection from arthritis in tumour necrosis factor α (TNF α) transgenic mice vaccinated against TNF α
L Delavallée, H Le Buanec, N Bessis, E Assier, A Denys, B Bizzini, D Zagury, M-C Boissier

Concise reports

- 1339** Effect of intra-articular infliximab on synovial membrane pathology in a patient with a seronegative spondyloarthropathy
M J Ahern, D G Campbell, H Weedon, V Papangelis, M D Smith
- 1343** Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients
L Josselin, A Mahr, P Cohen, C Pagnoux, G Guaydier-Souquières, G Hayem, C Job-Deslandre, F Liferman, J Pourrat, L Guillevin
- 1347** The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels
W H Bos, J Urum, N de Vries, G M Bartelds, G J Wolbink, M T Nurmohamed, I E van der Horst-Bruinsma, R J van de Stadt, J B A Crusius, P P Tak, B A C Dijkmans, D van Schaardenburg

Letters

- 1351** Extremity magnetic resonance imaging assessment of synovitis (without contrast) in rheumatoid arthritis may be less accurate than power Doppler ultrasound
J E Freeston, A K Brown, E M A Hensor, P Emery, P G Conaghan
- 1352** Efficacy of rituximab in Felty's syndrome
V Lekharaju, C Chattopadhyay
- 1352** *GDF5* Polymorphism associated with osteoarthritis: risk for rheumatoid arthritis
A Martínez, J Varadé, J R Lamas, M Fernández-Arquero, J A Jover, E G de la Concha, B Fernández-Gutiérrez, E Urcelay
- 1354** Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
N Gašperšič, I Serša, V Jevtič, M Tomšič, S Praprotnik
- 1354** Anti-collagen type II antibodies in patients with very early synovitis
K Raza, M Mullazehi, M Salmon, C D Buckley, J Rönnelid

PostScript

- 1356** Matters arising
- 1356** Correction



Take the pain out of research every month

Annals of the Rheumatic Diseases is the premier clinical rheumatology journal in Europe with an impressive impact factor of 5.767, so you'll want the guarantee of reading it every month.

Why not recommend the journal to your librarian or better still, obtain your own personal subscription? You will receive a paper copy every month as well as online access for **just £212 a year** (€314, \$403). Too much paper on your desk already? An online subscription is **just £99** (€147, \$188).

Visit group.bmj.com/group/subs-sales - your subscription to this first class journal is just a few clicks away.

ard.bmj.com**BMJ Journals**